Francois Cedric, CEO of Apellis Pharmaceuticals ($APLS), sold shares on the open market eight times in the last year, totaling $10.5 million. His most recent sale occurred on January 22, 2026. These sales rank him 1,080th among 11,678 insiders by total value sold, above the average of $8.6 million across 6.4 transactions per insider. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 64869 | $0.00 | 1,805,259.0000 | 130,067,000 | 3.73% | 0.05% |
| March 11, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 64869 | $0.00 | 1,805,259.0000 | 130,067,000 | 3.47% | 0.05% |
| Feb. 3, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 8840 | $3.76 | 1,805,259.0000 | 130,067,000 | 0.49% | 0.01% |
| Feb. 3, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 8840 | $0.00 | 0.0000 | 130,067,000 | 100.00% | 0.01% |
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Common Stock | 195952 | $0.00 | 1,796,419.0000 | 130,067,000 | 12.24% | 0.15% |
| Jan. 22, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 27192 | $21.77 | 1,600,467.0000 | 130,067,000 | 1.67% | 0.02% |
| Jan. 20, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 8182 | $19.79 | 1,627,659.0000 | 130,067,000 | 0.50% | 0.01% |
| Jan. 13, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 10186 | $22.19 | 1,635,841.0000 | 130,067,000 | 0.62% | 0.01% |
| Aug. 28, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 49963 | $28.39 | 1,646,027.0000 | 123,905,000 | 2.95% | 0.04% |
| Aug. 27, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 175037 | $28.19 | 1,695,990.0000 | 123,905,000 | 9.36% | 0.14% |
| July 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 8997 | $0.00 | 100,538.0000 | 123,905,000 | 8.21% | 0.01% |
| July 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 19725 | $20.21 | 1,871,027.0000 | 123,905,000 | 1.04% | 0.02% |
| July 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 8997 | $4.31 | 1,890,752.0000 | 123,905,000 | 0.48% | 0.01% |
| July 15, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 800 | $0.00 | 109,535.0000 | 123,905,000 | 0.73% | 0.00% |
| July 14, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 65203 | $4.31 | 2,020,320.0000 | 123,905,000 | 3.33% | 0.05% |
| July 14, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 137465 | $20.19 | 1,882,855.0000 | 123,905,000 | 6.80% | 0.11% |
| July 15, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 800 | $4.31 | 1,883,655.0000 | 123,905,000 | 0.04% | 0.00% |
| July 15, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 1900 | $20.09 | 1,881,755.0000 | 123,905,000 | 0.10% | 0.00% |
| July 14, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 65203 | $0.00 | 110,335.0000 | 123,905,000 | 37.14% | 0.05% |
| June 9, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Stock Option (Right to Buy) | 287500 | $19.39 | 287,500.0000 | 123,905,000 | 9999.99% | 0.23% |
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 2824 | $29.52 | 1,955,117.0000 | 123,905,000 | 0.14% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 13551 | $30.43 | 1,957,941.0000 | 123,905,000 | 0.69% | 0.01% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 6007 | $29.96 | 1,840,830.0000 | 123,905,000 | 0.33% | 0.00% |
| Jan. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Common Stock | 130662 | $0.00 | 1,971,492.0000 | 123,905,000 | 7.10% | 0.11% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 6247 | $28.70 | 1,846,837.0000 | 123,905,000 | 0.34% | 0.01% |
| Nov. 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | J | Common Stock | 182146 | $0.00 | 1,853,084.0000 | 124,234,000 | 8.95% | 0.15% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 41704 | $62.96 | 2,214,658.0000 | 118,678,000 | 1.85% | 0.04% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 62503 | $64.26 | 2,152,155.0000 | 118,678,000 | 2.82% | 0.05% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 116512 | $64.92 | 2,035,643.0000 | 118,678,000 | 5.41% | 0.10% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 413 | $65.68 | 2,035,230.0000 | 118,678,000 | 0.02% | 0.00% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 50000 | $0.00 | 8,840.0000 | 118,678,000 | 84.98% | 0.04% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 200000 | $0.00 | 175,538.0000 | 118,678,000 | 53.26% | 0.17% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 50000 | $3.76 | 2,085,230.0000 | 118,678,000 | 2.46% | 0.04% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 200000 | $4.31 | 2,285,230.0000 | 118,678,000 | 9.59% | 0.17% |
| March 1, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 28868 | $62.21 | 2,256,362.0000 | 118,678,000 | 1.26% | 0.02% |
| Feb. 12, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 3962 | $67.77 | 2,035,230.0000 | 118,678,000 | 0.19% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 2843 | $64.14 | 2,039,192.0000 | 118,678,000 | 0.14% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 13431 | $65.00 | 2,042,035.0000 | 118,678,000 | 0.65% | 0.01% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Stock Option (Right to Buy) | 104834 | $66.30 | 104,834.0000 | 118,678,000 | 9999.99% | 0.09% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 7851 | $66.81 | 2,055,466.0000 | 118,678,000 | 0.38% | 0.01% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Common Stock | 72094 | $0.00 | 2,063,317.0000 | 118,678,000 | 3.62% | 0.06% |
| Nov. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 5000 | $48.80 | 1,991,223.0000 | 106,114,000 | 0.25% | 0.00% |
| Sept. 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 150000 | $0.00 | 1,996,223.0000 | 106,114,000 | 6.99% | 0.14% |
| Sept. 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 150000 | $0.00 | 1,996,223.0000 | 106,114,000 | 8.12% | 0.14% |
| Sept. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 300000 | $0.00 | 0.0000 | 106,114,000 | 100.00% | 0.28% |
| Sept. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 10284 | $42.44 | 1,996,223.0000 | 106,114,000 | 0.51% | 0.01% |
| Sept. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 139716 | $41.70 | 2,006,507.0000 | 106,114,000 | 6.51% | 0.13% |
| Sept. 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 300000 | $2.67 | 2,146,223.0000 | 106,114,000 | 16.25% | 0.28% |
| May 24, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 20000 | $0.00 | 1,846,223.0000 | 106,114,000 | 1.07% | 0.02% |
| May 24, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 20000 | $0.00 | 1,846,223.0000 | 106,114,000 | 1.10% | 0.02% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 3007 | $85.90 | 1,835,871.0000 | 106,114,000 | 0.16% | 0.00% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 30000 | $2.67 | 1,856,223.0000 | 106,114,000 | 1.64% | 0.03% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 934 | $83.17 | 1,855,289.0000 | 106,114,000 | 0.05% | 0.00% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 1800 | $83.85 | 1,853,489.0000 | 106,114,000 | 0.10% | 0.00% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 14611 | $85.01 | 1,838,878.0000 | 106,114,000 | 0.79% | 0.01% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 7528 | $87.02 | 1,828,343.0000 | 106,114,000 | 0.41% | 0.01% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 2120 | $87.67 | 1,826,223.0000 | 106,114,000 | 0.12% | 0.00% |
| May 17, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 20000 | $2.67 | 1,846,223.0000 | 106,114,000 | 1.10% | 0.02% |
| May 16, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 320,000.0000 | 106,114,000 | 8.57% | 0.03% |
| May 17, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 300,000.0000 | 106,114,000 | 6.25% | 0.02% |
| April 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 382946 | $0.00 | 1,826,223.0000 | 106,114,000 | 17.33% | 0.36% |
| April 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 382946 | $0.00 | 1,826,223.0000 | 106,114,000 | 26.53% | 0.36% |
| April 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 20000 | $2.67 | 1,826,223.0000 | 106,114,000 | 1.11% | 0.02% |
| April 18, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 30000 | $2.67 | 1,836,223.0000 | 106,114,000 | 1.66% | 0.03% |
| April 19, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 350,000.0000 | 106,114,000 | 5.41% | 0.02% |
| April 18, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 370,000.0000 | 106,114,000 | 7.50% | 0.03% |
| April 18, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 30000 | $82.02 | 1,806,223.0000 | 106,114,000 | 1.63% | 0.03% |
| April 4, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 380000 | $0.00 | 1,833,213.0000 | 106,114,000 | 17.17% | 0.36% |
| April 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 26990 | $0.00 | 1,806,223.0000 | 106,114,000 | 1.47% | 0.03% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 227221 | $0.00 | 1,399,233.0000 | 106,114,000 | 19.39% | 0.21% |
| April 4, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 380000 | $0.00 | 1,779,233.0000 | 106,114,000 | 27.16% | 0.36% |
| April 5, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 26990 | $0.00 | 1,806,223.0000 | 106,114,000 | 1.52% | 0.03% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | G | Common Stock | 227221 | $0.00 | 2,213,213.0000 | 106,114,000 | 9.31% | 0.21% |
| March 22, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 7221 | $0.00 | 273,779.0000 | 106,114,000 | 2.57% | 0.01% |
| March 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 30000 | $2.67 | 1,709,002.0000 | 106,114,000 | 1.79% | 0.03% |
| March 22, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 20000 | $0.00 | 400,000.0000 | 106,114,000 | 4.76% | 0.02% |
| March 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 30000 | $0.00 | 420,000.0000 | 106,114,000 | 6.67% | 0.03% |
| March 22, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 7221 | $13.85 | 1,806,223.0000 | 106,114,000 | 0.40% | 0.01% |
| March 22, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 100000 | $3.76 | 1,799,002.0000 | 106,114,000 | 5.89% | 0.09% |
| March 22, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 20000 | $2.67 | 1,699,002.0000 | 106,114,000 | 1.19% | 0.02% |
| March 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | S | Common Stock | 30000 | $62.74 | 1,679,002.0000 | 106,114,000 | 1.76% | 0.03% |
| March 22, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 100000 | $0.00 | 58,840.0000 | 106,114,000 | 62.96% | 0.09% |
| Feb. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Common Stock | 100000 | $3.76 | 1,679,002.0000 | 106,114,000 | 6.33% | 0.09% |
| Feb. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | M | Stock Option (Right to Buy) | 100000 | $0.00 | 158,840.0000 | 106,114,000 | 38.63% | 0.09% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Stock Option (Right to Buy) | 19728 | $0.00 | 19,728.0000 | 106,114,000 | 9999.99% | 0.02% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | F | Common Stock | 1602 | $58.50 | 1,579,002.0000 | 106,114,000 | 0.10% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Common Stock | 13908 | $0.00 | 1,580,604.0000 | 106,114,000 | 0.89% | 0.01% |
| Feb. 10, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | F | Common Stock | 3958 | $51.21 | 1,566,696.0000 | 106,114,000 | 0.25% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | F | Common Stock | 2879 | $52.77 | 1,570,654.0000 | 106,114,000 | 0.18% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | F | Common Stock | 9453 | $52.05 | 1,573,533.0000 | 106,114,000 | 0.60% | 0.01% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Stock Option (Right to Buy) | 131093 | $52.66 | 131,093.0000 | 106,114,000 | 9999.99% | 0.12% |
| April 25, 2022 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | J | Stock Option (Right to Buy) | 75000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Francois Cedric | Chief Executive Officer | A | Common Stock | 83447 | $0.00 | 1,582,986.0000 | 106,114,000 | 5.56% | 0.08% |